# Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

> **NCT05164341** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amryt Pharma** · enrollment: 69 (actual)

## Conditions studied

- Partial Lipodystrophy

## Interventions

- **DRUG:** metreleptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05164341
- **Lead sponsor:** Amryt Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-17
- **Primary completion:** 2026-07-21
- **Final completion:** 2026-10-31
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164341, "Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05164341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*